tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

HOWL Stock Latest News

Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects
RatingsPromising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects
23d ago
HOWL
Unlocking Broader Therapeutic Potential: Andrew Fein’s Buy Rating on Werewolf Therapeutics
PremiumRatings
Unlocking Broader Therapeutic Potential: Andrew Fein’s Buy Rating on Werewolf Therapeutics
24d ago
HOWL
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China
PremiumCompany Announcements
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China
24d ago
HOWL
Werewolf Therapeutics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Werewolf Therapeutics Reports 2024 Financial Results and Progress
24d ago
HOWL
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c)
PremiumThe Fly
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c)
25d ago
HOWL
Werewolf Therapeutics sees cash runway through 2Q26
PremiumThe FlyWerewolf Therapeutics sees cash runway through 2Q26
25d ago
HOWL
Werewolf Therapeutics Appoints Anil Singhal to Board
Premium
Company Announcements
Werewolf Therapeutics Appoints Anil Singhal to Board
1M ago
8K
HOWL
Werewolf Therapeutics appoints Anil Singhal to board of directors
Premium
The Fly
Werewolf Therapeutics appoints Anil Singhal to board of directors
1M ago
HOWL
Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities
PremiumThe Fly
Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities
3M ago
HOWL
Werewolf Therapeutics provides business update, highlights 2025 outlook
PremiumThe Fly
Werewolf Therapeutics provides business update, highlights 2025 outlook
3M ago
HOWL
Werewolf Therapeutics Advances Innovative Cytokine Therapies
PremiumCompany Announcements
Werewolf Therapeutics Advances Innovative Cytokine Therapies
5M ago
8K
HOWL
Werewolf Therapeutics presents preclinical, clinical data on WTX-330
PremiumThe Fly
Werewolf Therapeutics presents preclinical, clinical data on WTX-330
5M ago
HOWL
Werewolf Therapeutics reports Q3 EPS (38c), consensus (41c)
PremiumThe FlyWerewolf Therapeutics reports Q3 EPS (38c), consensus (41c)
5M ago
HOWL
Werewolf Therapeutics sees cash runway through 2Q26
Premium
The Fly
Werewolf Therapeutics sees cash runway through 2Q26
5M ago
HOWL
Werewolf Therapeutics announces addition of WTX-921 to pipeline
Premium
The Fly
Werewolf Therapeutics announces addition of WTX-921 to pipeline
5M ago
HOWL
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & Ideas
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
6M ago
HOWL
IBTA
Werewolf Therapeutics reports Q2 EPS (43c), consensus (38c)
PremiumThe Fly
Werewolf Therapeutics reports Q2 EPS (43c), consensus (38c)
8M ago
HOWL
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
PremiumCompany Announcements
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes
9M ago
8K
HOWL
Werewolf announces initial trial results evaluating INDUKINE for lymphoma
PremiumThe Fly
Werewolf announces initial trial results evaluating INDUKINE for lymphoma
9M ago
HOWL
Werewolf Therapeutics’ Promising WTX-124 Clinical Trial Outcomes
PremiumCompany AnnouncementsWerewolf Therapeutics’ Promising WTX-124 Clinical Trial Outcomes
10M ago
8K
HOWL
Werewolf Therapeutics presents data from ongoing Phase 1/1b trial of WTX-124
Premium
The Fly
Werewolf Therapeutics presents data from ongoing Phase 1/1b trial of WTX-124
10M ago
HOWL
Werewolf Therapeutics sees cash runway through at least 1Q26
Premium
The Fly
Werewolf Therapeutics sees cash runway through at least 1Q26
11M ago
HOWL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >